보툴리눔톡신(보톡스) CDMO 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global botulinum toxin CDMO market size is expected to reach USD 7.64 Billion in 2034 from USD 2.84 Billion in 2025, growing at a CAGR of 11.62 during 2026-2034.This market is witnessing robust growth as pharmaceutical and biotechnology companies increasingly outsource the development and manufacturing of botulinum toxin products to specialized contract development and manufacturing organizations. Rising demand for aesthetic procedures, therapeutic applications, and biologic medicines is encouraging investments in advanced manufacturing capabilities. Growing regulatory requirements and the need for specialized production expertise are further accelerating outsourcing activities across the pharmaceutical industry.

Contract development and manufacturing organizations are expanding their facilities with advanced bioprocessing technologies, aseptic manufacturing systems, and quality assurance capabilities to support increasing global demand. Companies are investing in process optimization, analytical testing, and regulatory compliance to ensure consistent product quality. Strategic collaborations between biotechnology innovators and CDMOs are improving manufacturing efficiency while reducing product development timelines.

Future growth is expected to be supported by expanding therapeutic indications, increasing demand for minimally invasive cosmetic treatments, and continuous advancements in biologics manufacturing technologies. Automation, digital quality management systems, and advanced process control solutions will enhance production efficiency and regulatory compliance. Rising investments in research, manufacturing capacity, and global commercialization will continue creating significant long-term opportunities for the industry.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product

• Type A Botulinum Toxin
• Type B Botulinum Toxin

By Service

• Contract Development (Formulation Development, Process Development and Scale-Up, Analytical and Testing Services, Others)
• Contract Manufacturing (Clinical Manufacturing, Commercial Manufacturing)
• Packaging & Labelling
• Regulatory Affairs
• Supply Chain & Logistics
• Others

By Application

• Therapeutic
• Aesthetic

By End Use

• Pharmaceutical Companies
• Biotechnology Companies
• Aesthetic & Specialty Companies

COMPANIES PROFILED

• Boehringer Ingelheim BioXcellence GmbH, Catalent Inc., FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Gland Pharma (including Cenexi SAS assets), Grand River Aseptic Manufacturing Inc., Lonza Group AG, Recipharm AB, Samsung Biologics Co. Ltd., Thermo Fisher Scientific Inc., Vetter Pharma-Fertigung GmbH & Co. KG, WuXi Biologics (Cayman) Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BOTULINUM TOXIN CDMO MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Type A Botulinum Toxin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Type B Botulinum Toxin Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BOTULINUM TOXIN CDMO MARKET: BY SERVICE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Service
• 5.2. Contract Development (Formulation Development, Process Development and Scale-Up, Analytical and Testing Services, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Contract Manufacturing (Clinical Manufacturing, Commercial Manufacturing) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Packaging & Labelling Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Regulatory Affairs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Supply Chain & Logistics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BOTULINUM TOXIN CDMO MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Therapeutic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Aesthetic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BOTULINUM TOXIN CDMO MARKET: BY END USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End Use
• 7.2. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Aesthetic & Specialty Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BOTULINUM TOXIN CDMO MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product
  • 8.2.2 By Service
  • 8.2.3 By Application
  • 8.2.4 By End Use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product
  • 8.3.2 By Service
  • 8.3.3 By Application
  • 8.3.4 By End Use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product
  • 8.4.2 By Service
  • 8.4.3 By Application
  • 8.4.4 By End Use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product
  • 8.5.2 By Service
  • 8.5.3 By Application
  • 8.5.4 By End Use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product
  • 8.6.2 By Service
  • 8.6.3 By Application
  • 8.6.4 By End Use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL BOTULINUM TOXIN CDMO INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Boehringer Ingelheim BioXcellence GmbH
  • 10.2.2 Catalent Inc
  • 10.2.3 FUJIFILM Diosynth Biotechnologies U.S.A. Inc
  • 10.2.4 Gland Pharma (including Cenexi SAS Assets)
  • 10.2.5 Grand River Aseptic Manufacturing Inc
  • 10.2.6 Lonza Group AG
  • 10.2.7 Recipharm AB
  • 10.2.8 Samsung Biologics Co. Ltd
  • 10.2.9 Thermo Fisher Scientific Inc
  • 10.2.10 Vetter Pharma-Fertigung GmbH & Co. KG
  • 10.2.11 WuXi Biologics (Cayman) Inc